LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma.

Wang, Junbin; Liu, Jixian; Hou, Qinghua; Xu, Mengmeng

Wang, Junbin; Liu, Jixian; Hou, Qinghua; Xu, Mengmeng.

Affiliation

Wang J; Department of Thoracic Surgery, Peking University Shenzhen Hospital, No. 1120 Lianhua Road, Futian District, Shenzhen, 518034, Guangdong, China.
Liu J; Department of Thoracic Surgery, Peking University Shenzhen Hospital, No. 1120 Lianhua Road, Futian District, Shenzhen, 518034, Guangdong, China. zhongjh202112@163.com.
Hou Q; Department of Thoracic Surgery, Peking University Shenzhen Hospital, No. 1120 Lianhua Road, Futian District, Shenzhen, 518034, Guangdong, China.
Xu M; HaploX Biotechnology, Shenzhen, China.

BMC Pulm Med ; 22(1): 412, 2022 Nov 10.

Article in En | MEDLINE | ID: mdl-36357869

Subject(s)

Adenocarcinoma of Lung; Lung Neoplasms; Humans; Prognosis; ErbB Receptors/genetics; Adenocarcinoma of Lung/diagnosis; Adenocarcinoma of Lung/genetics; Lung Neoplasms/diagnosis; Lung Neoplasms/genetics; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; Immunotherapy; Gene Expression Regulation, Neoplastic; Tumor Microenvironment/genetics

Key words

Diagnosis; Immune cells; LINC02126; Lung adenocarcinoma; Prognosis; Tumor mutation burden

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma of Lung / Lung Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: BMC Pulm Med Year: 2022 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google